Shed will manage patient acquisition, clinical operations, and platform delivery, while LTR Pharma supplies the intranasal technology. ROXUS aims to capture market share from traditional oral medications by offering a delivery system that can trigger results in as little as five minutes. According to LTR Pharma’s Phase II interim clinical data, the treatment demonstrated a median Tmax of 10 minutes following administration.
In section Releases
Shed and LTR Pharma finalize U.S. launch for ROXUS intranasal spray
A new commercial partnership between Salt Lake City-based Shed and LTR Pharma is set to introduce ROXUS, a rapid-onset intranasal treatment for erectile dysfunction, to the U.S. market. The deal transitions a previous term sheet into a formal framework, positioning the drug as the flagship offering for the Mavrox men's health platform.
Morley Baker, CEO of Shed and Mavrox, identified the product as a rare innovation in a stagnant category. The company has already opened an early-access waitlist on the Mavrox website to gauge consumer interest ahead of the formal rollout. While the product is being marketed as a significant shift in erectile dysfunction care, the companies note that ROXUS remains a compounded prescription medication and has not yet received formal U.S. Food and Drug Administration approval. Patients will be required to undergo a clinical evaluation by a licensed provider before gaining access to the treatment.
Comments (0)
No comments yet. Be the first!